Peter Culpepper is the CFO and COO of Provectus Biopharmaceuticals. Aside from leading the company into developing therapies to destroy the deadliest cancers, Peter Culpepper is involved with the American Cancer Society which recently published an article on the development of a revolutionary colon cancer screening test.
Colonoscopy is one way for doctors to find colon cancer. The invasive procedure has been known to cause jitters in many, even more so when considering the bowel clearing preparations that go with it.
Developments in testing for colon cancer have led to the innovation of a new non-intrusive test for screening. The test, known as a stool DNA test, uses the patient’s stool to look for specific gene changes associated with cancer cells.
Approved by the FDA in 2014, the test has patients collecting samples of their stools and mailing them to labs. The stool is then checked for two things indicative of cancer: changes in DNA and traces of blood.
No special diet is needed for the test, neither are laxatives and enemas for bowel preparation.
The test is only available for patients with no history of colon cancer, precancerous polyps, or certain colon problems.